Form 4: IN8BIO Chief Operating Officer Kate Rochlin Reports Changes in Beneficial Ownership
SEC Form 4
Kate Rochlin, Chief Operating Officer of IN8BIO, INC., reports the acquisition and disposal of common stock and warrants related to Issuer Units.
Summary
- On October 4, 2024, Kate Rochlin, the Chief Operating Officer of IN8BIO, INC., reported changes in her beneficial ownership of the company's securities.
- Rochlin acquired 25,316 shares of common stock through the purchase of Issuer Units at $0.395 per unit, each unit containing one share of common stock and one Series C warrant.
- She also acquired 12,295 Series A warrants with an exercise price of $0.45 and an expiration date of October 4, 2025.
- The report also details an amendment of an existing warrant, where the exercise price was reduced from $1.25 to $0.45, and the expiration date was extended from June 13, 2025, to October 4, 2025.
- Following these transactions, Rochlin directly owns 42,874 shares of common stock and various warrants.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports transactions without expressing a clear positive or negative outlook. The COO's purchase of units could be seen as a slightly positive signal.
Positives
- The COO's investment in Issuer Units demonstrates confidence in the company's future.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to investors.
Comparison to Industry Standards
- Tracking insider transactions is a common practice in financial analysis.
- Comparing the size and frequency of insider buys and sells to those of peer companies can provide insights into management's sentiment and expectations for the company's performance.
- However, without additional context, it's difficult to determine if these transactions are significant compared to industry benchmarks.
Stakeholder Impact
- The transactions may influence investor perception of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 12/13/2023 | Original grant date of Series A warrants with an exercise price of $1.25 and expiration date of June 13, 2025. |
| 06/13/2025 | Original expiration date of Series A warrants before amendment. |
| 10/04/2024 | Date of transaction and amendment of warrants. |
| 10/04/2025 | New expiration date of Series A warrants after amendment. |
| 10/04/2027 | Expiration date of Series C warrants. |
| 10/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.